Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
tyrosine kinase inhibitors
Biotech
Galapagos' last immunology asset posts mixed results
The company’s TYK2 inhibitor met the primary endpoint in a dermatomyositis study but failed to do the same in systemic lupus erythematosus.
Darren Incorvaia
Dec 19, 2025 6:05am
Takeda looks to 2026 FDA filing for Sotyktu rival zasocitinib
Dec 18, 2025 7:55am
ESMO: Exelixis' TKI reduces risk of death by 20%
Oct 20, 2025 2:30am
Nuvalent trots out strong pivotal data in FDA lung cancer push
Jun 24, 2025 6:30am
Exelixis beats Bayer drug in cancer trial, sending stock higher
Jun 23, 2025 7:30am
Alumis hits stride as TYK2 inhibitor improves psoriasis in ph. 2
Mar 9, 2024 12:00pm
